Celebrating Women in Bio: The Launch of the 2025 Boardroom Ready Cohort

Introduction

Women In Bio (WIB), in partnership with Latham & Watkins, proudly reveals its latest cohort for the Boardroom Ready program. This initiative focuses on enhancing networking, community building, and collaborative opportunities for women within the biotechnology and life sciences sectors.

The Boardroom Ready Program

The Boardroom Ready program has garnered recognition for its effective executive development platform, designed specifically to boost women's representation on corporate boards. Participants engage in a tailored curriculum comprising various courses and hands-on learning sessions, enabling them to acquire critical insights essential for securing board appointments.

Dr. Kate Hillier, a partner at Latham & Watkins, expressed her enthusiasm for this initiative: "We’re proud to support the Boardroom Ready program and help create opportunities for professionals to elevate their role within biotech and life sciences companies across the U.S. and around the world. These driven, innovative leaders will bring a new perspective to the boardroom."

Profiles of the 2025 Cohort

The 2025 cohort includes an impressive array of trailblazers in the field, each representing a diverse background and expertise in biotech and life sciences. The selected candidates for this year’s program are:

- Alicia Palladino: Partner, Life Sciences IP Transactions, Goodwin Procter LLP
- Chaya Patel: Principal, Mission BioCapital
- Christine Garrett: Consultant, Garrett Life Sciences Consulting
- Courtney Phillips: Founder and CEO, Matrix Fluidix
- Deanna Angello: Former Chief Commercial Officer
- Eleonora Goldberg: Vice President, Medical Affairs, Arrowhead Pharmaceuticals
- Emilie Pelletier: CEO/Capital Project Lead and Program Manager, Orchestra Life Sciences
- Ivana Mikic: CEO/CTO, Diffine
- Kate Skrable: Vice President II, Strategic Partnerships SSF Site Head, Pfizer
- Lesley Northrop: Chief Diagnostics Officer, Laboratory Diagnostics Genomics Innovation, LLC
- Megan Shaw: President & CEO, Pittsburgh Life Sciences Alliance
- Michelle Lim-Watson: Vice President, Clinical Development and Program Leadership, Cardiomyopathy, Novo Nordisk
- Stephanie Astrow: Chief Scientific Officer, Chimeric Therapeutics
- Sybil Tasker: Chief Medical Officer, Inventprise, Inc.

The Role of Latham & Watkins

Latham & Watkins' commitment to this program has facilitated the expansion of the Executive Women In Bio (EWIB), a significant resource serving executive women in the life sciences community. EWIB focuses on empowering leaders by providing robust professional development programs, specialized networking events, and fostering exclusive communities that support and uplift one another. All WIB offerings are open to anyone interested in promoting diversity and inclusion within the life sciences industry.

Conclusion

Women In Bio has built a vibrant community that empowers women from all backgrounds across the life sciences. With nearly 4,000 members and over 12,000 individuals engaging in programming across 13 North American chapters, WIB is dedicated to supporting women at every stage of their careers—from students to board members. Through mentorship, networking, and innovative programming, women joining WIB can access invaluable resources and support essential for advancing their careers in life sciences. As we witness this cohort embark on their journey, the future of women in biotech and life sciences looks promising and full of potential.